PATENT CLAIM ANALYSIS

Application Number: 16067327
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "924000"]

Abstract:
Use of carrimycin in  mycobacterium tuberculosis  infection resistance comprises the main steps: measuring the activity of carrimycin in  mycobacterium tuberculosis  resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated  mycobacterium tuberculosis  including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle  bacillus  infected diseases are expected to be developed.

Claim (Index 4):
A method for treating  mycobacterium tuberculosis  infection, comprising administering an effective amount of carrimycin to a subject.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 94.0
- Lexical Diversity: 1.50794
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12088867', '10844992', '12255976', '15829188', '13503625']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7687007198184183
- 35 USC 102 Novelty (BERT): 0.4914139889094882
- Combined Prediction Score: 0.7409720467275253
- Mean Citation Score: 219.170178
- Max Citation Score: 224.08434
- Similarity Product: 161.19869853586437

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test